Results found: 3

Number of results on page

Search results

Search:
in the keywords: ablation

Sort By:

Limit search:

Periprocedural decrease in tumor necrosis factor alpha is a risk factor for atrial fibrillation recurrence after ablation

100%

Szczerba E., Koźluk E., Januszkiewicz Ł., Lisicka M., Nowak J., Kondracka A., Majstrak J., Rodkiewicz D., Piątkowska A., Kiliszek M., Opolski G.

Background Concentration of tumor necrosis factor alpha (TNF-alpha) might be useful in selecting patients with paroxysmal atrial fibrillation (PAF) who will benefit the most from pulmonary vein isolation. Material and methods We performed prospective cohort study among patients with PAF who had sinus rhythm prior to undergoing either radiofrequency ablation or cryoablation procedure. Blood samples were collected at the start of the procedure and 16-24 h after. TNF-alpha concentrations were measured. Follow-up data was obtained during a structured telephone interview and 24-hour ECG Holter monitoring 12 months after the ablation procedure. Results Thirty seven patients were enrolled. After 12-month follow-up 27 patients maintained sinus rhythm, 8 had recurrence of AF and 2 were lost to follow-up. There was no significant correlation between TNF-alpha concentrations in any of the samples and the recurrence of arrhythmia (for pre-procedural samples: 1.75 pg/ml vs 1.74 pg/ml; p=0.72; for post-procedural samples: 1.49 pg/ml vs 1.79 pg/ml; p=0.16). In patients who had a recurrence of AF, we observed a decrease in the periprocedural TNF-alpha concentration (-0.12 pg/ml vs 0.05 pg/ml; p=0.05). Conclusions Neither pre- nor post-procedural TNF-alpha concentrations are predictive of ablation outcome in patients with PAF. We observed a decrease in the periprocedural TNF-alpha concentration in patients who had AF recurrence.

Stereotactic management of arrhythmia – radiosurgery in treatment of ventricular tachycardia (SMART-VT) – clinical trial protocol and study rationale

88%

Miszczyk M., Jadczyk T., Tomasik B., Latusek T., Bednarek J., Kurzelowski R., Gołba K., Wojakowski W., Wita K., Dolla Ł., Grządziel A., Blamek S.

OncoReview

2020

vol. 10

issue 4

123-129

Patients with ventricular tachycardia are usually treated with antiarrhythmic drugs and ablation if the arrhythmia substrate is available for invasive treatment. Despite high efficiency of this treatment there is a significant group of patients who do not benefit from available treatment methods, either because they cannot be applied or do not allow for durable control of the disease. For that reason a novel treatment method, STereotactic Arrhythmia Radioablation (STAR) has been proposed and its safety and efficiency is extensively studied throughout the world. The method is based on irradiation of the arrhythmia substrate identified with electrophysiological examination with high-precision image-guided radiosurgical methods usually used for ablation of malignant tumors. Here we present the protocol of the first Polish study on STAR in patients with intractable ventricular tachycardia (STARVT, NCT04642963), designed to test the safety of the method. Secondary endpoints include measures of the treatment efficiency.

Ocena zmian wybranych markerów uszkodzenia mięśnia sercowego u pacjentów poddanych ablacji substratu arytmii prądem o częstotliwości radiowej

75%

Kaczmarek K., Poznański M., Ptaszyński P., Wranicz J. K., Ruta J.

Folia Medica Lodziensia

2010

vol. 37

issue 2

217-226

Radiofrequency ablation procedures are accepted method of treatment of cardiac arrhythmias. During current application small tissue damage occurs. We observed also the increasing serum level of myocardial injury markers. The troponin T level after ablation increases above normal range and reaches normal values within 72 hours. In contrast cardiac isoenzyme of creatynine kinase levels are increased longer than 3 days. There are no correlation between the time of procedure and current parameters and serum levels of myocardial injury markers.

Ablacja przezskórna jest uznaną metodą inwazyjnego leczenia zaburzeń rytmu serca. WiąŜe się ona z niewielkim uszkodzeniem miokardium będącym substratem arytmii. WiąŜe się to z uwolnieniem do krwi markerów martwicy mięśnia sercowego. Obserwujemy wzrost poziomu troponin sercowych, który ulega normalizacji w trzeciej dobie. StęŜenie izoenzymu sercowego kinazy kreatynowej (CK-MB) po zabiegach ablacji wzrasta, utrzymując się jednak zwykle w górnych zakresach normy. Aktywność CK-MB jest podwyŜszona w stosunku do wartości wyjściowych dłuŜej niŜ 72 godziny od zabiegu. Nie stwierdzono wpływu czasu trwania zabiegu, liczby aplikacji prądu o częstotliwości radiowej (RF – radiofrequency current) na stęŜenie markerów martwicy miokardium w surowicy i stęŜenie D-dimerów.

Refine search results

1 European Journal of Translational and Clinical Medicine

1 Folia Medica Lodziensia

1 OncoReview

1 2022

1 2020

1 2010

1 Bednarek J.

1 Blamek S.

1 Dolla Ł.

1 Gołba K.

1 Grządziel A.

1 Jadczyk T.

1 Januszkiewicz Ł.

1 Kaczmarek K.

1 Kiliszek M.

1 Kondracka A.

1 Koźluk E.

1 Kurzelowski R.

1 Latusek T.

1 Lisicka M.

1 Majstrak J.

1 Miszczyk M.

1 Nowak J.

1 Opolski G.

1 Piątkowska A.

1 Poznański M.

1 Ptaszyński P.

1 Rodkiewicz D.

1 Ruta J.

1 Szczerba E.

1 Tomasik B.

1 Wita K.

1 Wojakowski W.

1 Wranicz J. K.

Search results

Periprocedural decrease in tumor necrosis factor alpha is a risk factor for atrial fibrillation recurrence after ablation

Stereotactic management of arrhythmia – radiosurgery in treatment of ventricular tachycardia (SMART-VT) – clinical trial protocol and study rationale

Ocena zmian wybranych markerów uszkodzenia mięśnia sercowego u pacjentów poddanych ablacji substratu arytmii prądem o częstotliwości radiowej